News & Views - Page 39 of 53 - Telix Pharmaceuticals Limited

Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

Telix is pleased to announce that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor Relations.

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder cancer.

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line therapy.

Telix Update on FDA New Drug Application Review for Illuccix®

Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product Illuccix®.

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

Telix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied Radiology.

Scott Law joins Telix as SVP Global Manufacturing Operations

Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing Operations.

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA Association.

Telix Symposium at SNMMI 2021 Virtual Annual Meeting

Telix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15 June.

Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging

Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68 generator.

Telix to Present at the 2021 Jefferies Virtual Healthcare Conference

Telix is pleased to announce that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference 2021.